BioGeneration Ventures–Halle JP: management, 202404– Venture Partner before at Merck KGaA since 2005

	Period	2024-04-02
	Organisation	BioGeneration Ventures B.V. (BGV)
	Organisation 2	Merck KGaA
	Product	venture capital
	Product 2	pharmaceutical
	Person	Halle, Jörn-Peter (BioGeneration Ventures 202404– Venture Partner before at Merck KGaA since 2005)

BioGeneration Ventures B.V.. (4/2/24). "Press Release: BGV Appoints Peter Halle, PhD as Venture Partner". Amsterdam.

BioGeneration Ventures ("BGV"), a leading early-stage VC firm specializing in European biopharma, is delighted to announce the appointment of Dr. Joern-Peter Halle as Venture Partner further enriching the company's team, network and expertise in company establishment and development. With over 25 years of diverse experience in the biopharmaceutical sector, Dr. Halle joins BGV from his most recent role as Chief Strategy Officer at Merck KGaA's Healthcare division.

"We are thrilled to welcome Dr. Joern-Peter Halle to the BGV family. His deep expertise and strategic vision will be applied to our portfolio companies and new company creations, which greatly enhances their chance of success," remarked Managing Partner Oskar Slotboom upon his appointment.

"I am excited to join BGV and contribute to their mission of fostering innovation in the biopharma sector, driving positive impact for patients and society,” noted Dr Halle.

Dr Halle earned his Ph.D. (Dr. rer. nat.) in molecular biology from the University of Konstanz. Following his post-doctoral tenure at the Gene Center Munich, he co-founded a startup focusing on R&D in dermatology and serving as Chief Business Officer. Joining Merck KGaA in 2005 as part of the M&A/BD team, he played a pivotal role in the Serono acquisition and subsequent integration. Transitioning to Merck Healthcare, he assumed increasingly significant roles, including Head of External Innovation, membership in the Therapeutic Area Leadership Team Oncology, Head of Immuno-Oncology Research, and Global Head of Research. Dr Halle also played a key role in the establishment of M Ventures, Merck KGaA's corporate venture capital arm, and chaired its Healthcare Investment Committee.

-Ends-

For more information please contact:

Media Enquiries
Laura Asbjornsen, Head of Communications
Email: laura@biogeneration.vc
Tel: +31 (0)35 699 30 00

About BGV

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class companies. BGV manages over EUR 400 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together. BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.

BGV is the early-stage focused platform partner of Forbion, a leading European life sciences venture capital fund with €3 billion in capital under management, and is based in Naarden, The Netherlands. For more information, please visit: For more information, please visit: www.biogenerationventures.com